New Immune-Blocking drug tested in humans for first time

NCT ID NCT06797375

Completed Disease control Sponsor: Rallybio Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested RLYB116, a small protein that blocks a part of the immune system called complement, in 16 healthy adults. The main goal was to see if it is safe and how the body handles it. Researchers also checked how well it stops complement activity. This is a first step toward possibly treating blood and autoimmune diseases.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RLYB116 (a small protein that blocks part of the immune system called complement)
What this could lead to: If successful, this could lead to a new treatment for blood and autoimmune diseases by controlling harmful immune activity.
What could go wrong: This is a very early, small study in healthy people, not patients. It only checks safety and drug levels, not whether it works for any disease. Side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease hematologic disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE DISEASES HEMATOLOGIC DISEASES

Contacts and locations

Locations

Nucleus Network Brisbane

Brisbane, Queensland, 4006, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.